Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Nvidia Partner Super Micro's Momentum Drops As Investors Shrug Off Earnings Surprise- Shares Approach 52-Week Low

Nvidia Partner Super Micro's Momentum Drops As Investors Shrug Off Earnings Surprise- Shares Approach 52-Week Low

FinvizFinviz2026/02/18 13:09
By:Finviz

NVIDIA Corp.(NASDAQ:NVDA) partner Super Micro Computer Inc. (NASDAQ:SMCI) is facing a stark disconnect between its robust fundamental performance and its technical market health.

Fundamental Strength Clashes With Market Sentiment

Despite reporting a massive second-quarter earnings beat, the stock's momentum score has collapsed from 16.26 to 6.35 week-on-week, according to the latest Benzinga Edge Stock Rankings.

This drop places the AI-server giant in the bottom 10% for relative strength, as investors appear to prioritize technical weakness over operational success.

The company posted adjusted earnings of $0.69 per share on revenue of $12.68 billion, easily topping consensus estimates of $0.49 and $10.21 billion, respectively.

While management raised full-year revenue guidance to $40 billion, the market’s reaction has been muted by ongoing volatility and analyst price target reductions from firms like Needham and Rosenblatt.

Benzinga Edge Rankings Reveal Deep Technical Erosion

While Super Micro maintains elite fundamental scores, including a quality rank of 98.52 and a growth rank of 82.57, its price-driven metrics have turned sharply negative.

The price trends for short, medium, and long terms are all currently flashing red.

SMCI is trading 34.11% below its 200-day simple moving average (SMA) of $41.69, as per Benzinga Pro, reflecting a mixed to bearish technical picture that has seen shares decrease by 46.04% over the past year.

Investor Outlook Amidst Momentum Decay

The combination of a neutral Relative Strength Index of 45.40 and a momentum score nearing zero suggests significant uncertainty in the stock's short-term trajectory.

Although the value rank of 80.49 indicates the stock may be underpriced relative to its assets and earnings, the weak momentum score serves as a warning for short-term traders.

Nvidia Partner Super Micro's Momentum Drops As Investors Shrug Off Earnings Surprise- Shares Approach 52-Week Low image 1

SMCI Underperforms In 2026

Shares of SMCI have declined by 2.75% year-to-date, while the Nasdaq Composite was down 2.83% in the same period.

The stock was down 2.83% over the last six months and 46.04% over the year. On Wednesday, the stock was 1.63% higher in premarket trading.

Image via Shutterstock

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales